My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
WA State Allocation Agreement of funds paid from Opioid Settlements
>
Meetings
>
2025
>
09. September
>
2025-09-16 10:00 AM - Commissioners' Agenda
>
WA State Allocation Agreement of funds paid from Opioid Settlements
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
9/11/2025 12:15:37 PM
Creation date
9/11/2025 12:14:08 PM
Metadata
Fields
Template:
Meeting
Date
9/16/2025
Meeting title
Commissioners' Agenda
Location
Commissioners' Auditorium
Address
205 West 5th Room 109 - Ellensburg
Meeting type
Regular
Meeting document type
Supporting documentation
Supplemental fields
Item
Request to Approve a Resolution Authorizing Acceptance and County Participation in the Washington State Allocation Agreement of Funds Paid by the Purdue Bankruptcy and Certain Opioid Manufactures and Authorizing Commissioner Signature on All Required Participation Forms
Order
2
Placement
Consent Agenda
Row ID
135628
Type
Resolution
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
50
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
OPIOID ABATEMENT STRATEGIES <br />PART ONE: TREATMENT <br />A. TREAT OPIOID USE DISORDER (OUD) <br />Support treatment of Opioid Use Disorder (OUD) and any co-occurring Substance Use <br />Disorder or Mental Health (SUD/MH) conditions, co-usage, and/or co-addiction through <br />evidence-based, evidence-informed, or promising programs or strategies that may include, <br />but are not limited to, the following: <br />1. Expand availability of treatment for OUD and any co-occurring SUD/MH conditions, <br />co-usage, and/or co-addiction, including all forms of Medication-Assisted Treatment <br />(MAT) approved by the U.S. Food and Drug Administration. <br />2. Support and reimburse services that include the full American Society of Addiction <br />Medicine (ASAM) continuum of care for OUD and any co-occurring SUD/MH <br />conditions, co-usage, and/or co-addiction, including but not limited to: <br />a. Medication-Assisted Treatment (MAT); <br />b. Abstinence-based treatment; <br />c. Treatment, recovery, or other services provided by states, subdivisions, <br />community health centers; non-for-profit providers; or for-profit providers; <br />d. Treatment by providers that focus on OUD treatment as well as treatment by <br />providers that offer OUD treatment along with treatment for other SUD/MH <br />conditions, co-usage, and/or co-addiction; or <br />e. Evidence-informed residential services programs, as noted below. <br />3. Expand telehealth to increase access to treatment for OUD and any co-occurring <br />SUD/MH conditions, co-usage, and/or co-addiction, including MAT, as well as <br />counseling, psychiatric support, and other treatment and recovery support services. <br />4. Improve oversight of Opioid Treatment Programs (OTPs) to assure evidence-based, <br />evidence-informed, or promising practices such as adequate methadone dosing. <br />5. Support mobile intervention, treatment, and recovery services, offered by qualified <br />professionals and service providers, such as peer recovery coaches, for persons with <br />OUD and any co-occurring SUD/MH conditions, co-usage, and/or co-addiction and <br />for persons who have experienced an opioid overdose. <br />6. Support treatment of mental health trauma resulting from the traumatic experiences of <br />the opioid user (e.g., violence, sexual assault, human trafficking, or adverse childhood <br />experiences) and family members (e.g., surviving family members after an overdose
The URL can be used to link to this page
Your browser does not support the video tag.